DE69332566T2 - Impfstoff enthaltend lebendes virus - Google Patents

Impfstoff enthaltend lebendes virus

Info

Publication number
DE69332566T2
DE69332566T2 DE69332566T DE69332566T DE69332566T2 DE 69332566 T2 DE69332566 T2 DE 69332566T2 DE 69332566 T DE69332566 T DE 69332566T DE 69332566 T DE69332566 T DE 69332566T DE 69332566 T2 DE69332566 T2 DE 69332566T2
Authority
DE
Germany
Prior art keywords
virus
avian
human
lyophilization
purifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332566T
Other languages
English (en)
Other versions
DE69332566D1 (de
Inventor
Laszlo K Csatary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNITED CANCER RES INST ALEXAND
Original Assignee
UNITED CANCER RES INST ALEXAND
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU9200966A external-priority patent/HU207297B/hu
Application filed by UNITED CANCER RES INST ALEXAND filed Critical UNITED CANCER RES INST ALEXAND
Application granted granted Critical
Publication of DE69332566D1 publication Critical patent/DE69332566D1/de
Publication of DE69332566T2 publication Critical patent/DE69332566T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69332566T 1992-03-24 1993-03-23 Impfstoff enthaltend lebendes virus Expired - Fee Related DE69332566T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU9200966A HU207297B (en) 1992-03-24 1992-03-24 Process for producing 4-hydroxy-7-chloro-quinoline
HU9226547 1992-08-17
PCT/US1993/002441 WO1993018790A1 (en) 1992-03-24 1993-03-23 Vaccine containing live virus for therapy of viral diseases and malignancies

Publications (2)

Publication Number Publication Date
DE69332566D1 DE69332566D1 (de) 2003-01-23
DE69332566T2 true DE69332566T2 (de) 2003-09-04

Family

ID=26318074

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332566T Expired - Fee Related DE69332566T2 (de) 1992-03-24 1993-03-23 Impfstoff enthaltend lebendes virus

Country Status (10)

Country Link
EP (1) EP0713397B1 (de)
KR (1) KR950700756A (de)
AT (1) ATE229344T1 (de)
AU (1) AU673827B2 (de)
CA (1) CA2132328C (de)
DE (1) DE69332566T2 (de)
DK (1) DK0713397T3 (de)
ES (1) ES2188593T3 (de)
PT (1) PT713397E (de)
WO (1) WO1993018790A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435155D1 (de) 1993-04-30 2008-12-04 Wellstat Biologics Corp Zusuammensetzungen zur Behandlung von Krebs mittels Viren
DE4422238C2 (de) * 1994-06-24 1996-05-30 Behringwerke Ag Verfahren zur Isolierung einer Antigenpräparation
EP0968284B1 (de) 1996-11-20 2006-12-13 Introgen Therapeutics, Inc. Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
GB9808922D0 (en) 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
ATE421337T1 (de) * 1998-11-16 2009-02-15 Introgen Therapeutics Inc Adenovirus-formulierungen zur gentherapie
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
EP1390046A4 (de) 1999-04-15 2005-04-20 Wellstat Biologics Corp Behandlung von neoplasmen mit viren
ES2260057T3 (es) 1999-09-17 2006-11-01 Wellstat Biologics Corporation Virus oncolitico.
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
WO2005066333A1 (en) * 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
JP2007517888A (ja) 2004-01-15 2007-07-05 インターベツト・インターナシヨナル・ベー・ベー 非動物由来安定剤およびその製造方法
WO2006052302A2 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying adenoviral vectors
WO2007014896A1 (en) 2005-07-29 2007-02-08 Solvay Pharmaceuticals Gmbh Processes for the manufacture of sterilized pancreatin powder
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ATE539148T1 (de) 2009-11-30 2012-01-15 United Cancer Res Inst Neuer klon des geflügelpestvirus, herstellung und anwendung bei der medizinischen behandlung von krebs
WO2012075379A2 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Liquid viral formulations
CA2819236A1 (en) 2010-12-02 2012-06-07 Oncolytics Biotech Inc. Lyophilized viral formulations
WO2023191628A1 (en) * 2022-03-30 2023-10-05 Bioneedle Drug Delivery B.V. A process for storing biologically active constructs in a biodegradable material

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US3874999A (en) * 1973-10-31 1975-04-01 American Cyanamid Co Process for the purification of virus vaccine
BE853923A (fr) * 1977-04-25 1977-10-25 Rit Rech Ind Therapeut Nouveau vaccin vivant ameliore contre le pseudopeste aviaire et son procede de preparation
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
HU197846B (en) * 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
HU197517B (en) * 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
DD229031A1 (de) * 1984-11-19 1985-10-30 Fi Fuer Lungenkrankheiten Und Verfahren zur herstellung eines oral-impfstoffes
DE3784513T2 (de) * 1986-08-04 1993-09-16 Us Commerce Menschlicher b-lymphotroper virus (hblv), isolierung und erzeugnisse.
US4824668A (en) * 1987-03-09 1989-04-25 Sterwin Laboratories Inc. Attenuated infectious bursal disease virus strain and vaccine therefrom
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
DE69132875T2 (de) * 1990-05-21 2002-08-22 Univ Tulane Assoziation zwischen einem menschlichen immunschwäche-virus verwandten retrovirus und dem sjoegren-syndrom

Also Published As

Publication number Publication date
EP0713397A4 (de) 1995-12-07
WO1993018790A1 (en) 1993-09-30
AU673827B2 (en) 1996-11-28
KR950700756A (ko) 1995-02-20
EP0713397A1 (de) 1996-05-29
ES2188593T3 (es) 2003-07-01
CA2132328A1 (en) 1993-09-30
AU3922293A (en) 1993-10-21
EP0713397B1 (de) 2002-12-11
DE69332566D1 (de) 2003-01-23
CA2132328C (en) 2000-10-31
ATE229344T1 (de) 2002-12-15
DK0713397T3 (da) 2003-03-31
PT713397E (pt) 2003-04-30

Similar Documents

Publication Publication Date Title
DE69332566T2 (de) Impfstoff enthaltend lebendes virus
CA1331444C (en) Ibdv production in continuous lines
Silva et al. Effects of hydrostatic pressure on a membrane-enveloped virus: high immunogenicity of the pressure-inactivated virus
BR9908424A (pt) Processo para purificar uma preparação de herpesvìrus
DE68915165D1 (de) Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
US4317811A (en) Herpes simplex type 1 subunit vaccine
DE3689622D1 (de) Impfstoffe gegen menschliche respiratorische viren.
Danner et al. In vitro studies on Borna virus: II. Properties of the virus
IL128804A (en) Method for preparing live virus, live chimeric virus obtained by method and vaccine containing the virus
US4302444A (en) Vaccines for immunizing egg-laying birds against Egg Drop disease, preparation of said vaccines, and method of use of said vaccines
CN103333242A (zh) scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
Budowsky et al. Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of β-propiolactone
CA2181862A1 (en) Mild newcastle disease virus vaccine
US4946676A (en) Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide
Cox The structural proteins of rabies virus
DZ1550A1 (fr) Vaccin depourvu de cellules contre le virus de la maladie marek.
RU2142816C1 (ru) Способ получения антигерпетической вакцины и лекарственная форма на ее основе
Carmichael et al. Small-plaque variant of canine herpesvirus with reduced pathogenicity for newborn pups
DK257887A (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
RU2195959C1 (ru) Инактивированная вакцина против синдрома гидроперикардита кур
Glück et al. New aspects concerning the immunogenicity of rabies vaccines produced in animal brains (duck embryo)
Grabowska et al. A sensitive method for NDV isolation using media modified by 5-iodo-2-deoxyuridine(IDU).
Xiaobin et al. Analysis of the Antigens of Detergent Disrupted Bovine Ephemeral Fever Virus
GB916803A (en) Vaccine for the protection of humans against trachoma
RU95104924A (ru) Штамм вируса герпеса кур "50" - деп для изготовления вакцины против болезни марека

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee